Alida L P Caforio1, Alvaro Izquierdo-Bajo1, Chun-Yan Cheng1, Petros Syrris2, Perry M Elliott2, Gaetano Thiene3, Cristina Basso3, Sabino Iliceto1, Federica Re4, Andrea Avella4, Renzo Marcolongo5, Pasquale Baratta4, Mara Seguso6, Nicoletta Gallo6, Mario Plebani6, Giulia d'Amati7, Dario Gregori8, Elisabetta Zachara4. 1. Division of Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (A.L.P.C, A.I.-B., C.-Y.C., S.I.), University of Padova, Italy. 2. University College London and Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, UK (P.S., P.M.E.). 3. Cardiovascular Pathology Unit (G.T., C.B.), University of Padova, Italy. 4. I Cardiology Division, San Camillo Hospital, Rome, Italy (F.R., A.A., P.B., E.Z.). 5. Department of Medicine, Hematology and Clinical Immunology (R.M.), University of Padova, Italy. 6. Department of Laboratory Medicine (M.S., N.G., M.P.), University of Padova, Italy. 7. Department of Radiological, Oncological, and Anatomo-pathological Sciences, Sapienza University of Rome, Italy (G.d'A.). 8. Statistics, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (D.G.), University of Padova, Italy.
Abstract
BACKGROUND: Serum anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in myocarditis. Myocarditis has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC). To provide evidence for autoimmunity, we searched for AHAs and AIDAs in ARVC. METHODS: We studied: 42 ARVC probands, 23 male, aged 42, interquartile range 33-49, 20 from familial and 22 nonfamilial pedigrees; 37 clinically affected relatives (ARs), 24 male aged 35, interquartile range 18-46; and 96 healthy relatives, 49 male, aged 27, interquartile range 17-45. Serum AHAs and AIDAs were tested by indirect immunofluorescence on human myocardium and skeletal muscle in 171 of the 175 ARVC individuals and in controls with noninflammatory cardiac disease (n=160), ischemic heart failure (n=141), and healthy blood donors (n=270). Screening of 5 desmosomal genes was performed in probands; when a sequence variant was identified, cascade family screening followed, blind to immunologic results. RESULTS: AHA frequency was higher (36.8%) in probands, ARs (37.8%), and healthy relatives (25%) than in noninflammatory cardiac disease (1%), ischemic heart failure (1%), or healthy blood donors (2.5%; P=0.0001). AIDA frequency was higher in probands (8%, P=0.006), in ARs (21.6%, P=0.00001), and in healthy relatives (14.6%, P=0.00001) than in noninflammatory cardiac disease (3.75%), ischemic heart failure (2%), or healthy blood donors (0.3%). AHA-positive status was associated with higher frequency of palpitation (P=0.004), implantable cardioverter defibrillator implantation (P=0.021), lower left ventricular ejection fraction (P=0.004), AIDA-positive status with both lower right ventricular and left ventricular ejection fractions (P=0.027 and P=0.027, respectively). AHA- and/or AIDA-positive status in the proband and at least one of the respective relatives was more common in familial (17/20, 85%) than in sporadic (10/22, 45%) pedigrees (P=0.007). CONCLUSIONS: The presence of AHAs and AIDAs provides evidence of autoimmunity in the majority of familial and in almost half of sporadic ARVC. In probands and in ARs, these antibodies were associated with features of disease severity. Longitudinal studies are needed to clarify whether they may predict ARVC development in healthy relatives or if they be a result of manifest ARVC.
BACKGROUND: Serum anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in myocarditis. Myocarditis has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC). To provide evidence for autoimmunity, we searched for AHAs and AIDAs in ARVC. METHODS: We studied: 42 ARVC probands, 23 male, aged 42, interquartile range 33-49, 20 from familial and 22 nonfamilial pedigrees; 37 clinically affected relatives (ARs), 24 male aged 35, interquartile range 18-46; and 96 healthy relatives, 49 male, aged 27, interquartile range 17-45. Serum AHAs and AIDAs were tested by indirect immunofluorescence on human myocardium and skeletal muscle in 171 of the 175 ARVC individuals and in controls with noninflammatory cardiac disease (n=160), ischemic heart failure (n=141), and healthy blood donors (n=270). Screening of 5 desmosomal genes was performed in probands; when a sequence variant was identified, cascade family screening followed, blind to immunologic results. RESULTS: AHA frequency was higher (36.8%) in probands, ARs (37.8%), and healthy relatives (25%) than in noninflammatory cardiac disease (1%), ischemic heart failure (1%), or healthy blood donors (2.5%; P=0.0001). AIDA frequency was higher in probands (8%, P=0.006), in ARs (21.6%, P=0.00001), and in healthy relatives (14.6%, P=0.00001) than in noninflammatory cardiac disease (3.75%), ischemic heart failure (2%), or healthy blood donors (0.3%). AHA-positive status was associated with higher frequency of palpitation (P=0.004), implantable cardioverter defibrillator implantation (P=0.021), lower left ventricular ejection fraction (P=0.004), AIDA-positive status with both lower right ventricular and left ventricular ejection fractions (P=0.027 and P=0.027, respectively). AHA- and/or AIDA-positive status in the proband and at least one of the respective relatives was more common in familial (17/20, 85%) than in sporadic (10/22, 45%) pedigrees (P=0.007). CONCLUSIONS: The presence of AHAs and AIDAs provides evidence of autoimmunity in the majority of familial and in almost half of sporadic ARVC. In probands and in ARs, these antibodies were associated with features of disease severity. Longitudinal studies are needed to clarify whether they may predict ARVC development in healthy relatives or if they be a result of manifest ARVC.
Entities:
Keywords:
arrhythmogenic right ventricular dysplasia; autoantibodies; autoimmunity
Authors: Stephane Heymans; James S Ware; Sanjay K Prasad; Amrit S Lota; Mark R Hazebroek; Pantazis Theotokis; Rebecca Wassall; Sara Salmi; Brian P Halliday; Upasana Tayal; Job Verdonschot; Devendra Meena; Ruth Owen; Antonio de Marvao; Alma Iacob; Momina Yazdani; Daniel J Hammersley; Richard E Jones; Riccardo Wage; Rachel Buchan; Fredrik Vivian; Yakeen Hafouda; Michela Noseda; John Gregson; Tarun Mittal; Joyce Wong; Jan Lukas Robertus; A John Baksi; Vassilios Vassiliou; Ioanna Tzoulaki; Antonis Pantazis; John G F Cleland; Paul J R Barton; Stuart A Cook; Dudley J Pennell; Pablo Garcia-Pavia; Leslie T Cooper Journal: Circulation Date: 2022-09-26 Impact factor: 39.918
Authors: J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson Journal: Circ Res Date: 2022-05-26 Impact factor: 23.213
Authors: Babken Asatryan; Angeliki Asimaki; Andrew P Landstrom; Mohammed Y Khanji; Katja E Odening; Leslie T Cooper; Francis E Marchlinski; Anna R Gelzer; Christopher Semsarian; Tobias Reichlin; Anjali T Owens; C Anwar A Chahal Journal: Circulation Date: 2021-11-15 Impact factor: 39.918
Authors: Viraj Patel; Babken Asatryan; Bhurint Siripanthong; Patricia B Munroe; Anjali Tiku-Owens; Luis R Lopes; Mohammed Y Khanji; Alexandros Protonotarios; Pasquale Santangeli; Daniele Muser; Francis E Marchlinski; Peter A Brady; C Anwar A Chahal Journal: Int J Mol Sci Date: 2020-09-10 Impact factor: 5.923
Authors: Maria Shoykhet; Sebastian Trenz; Ellen Kempf; Tatjana Williams; Brenda Gerull; Camilla Schinner; Sunil Yeruva; Jens Waschke Journal: JCI Insight Date: 2020-09-17